Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Smouldering acute myelogenous leukemia.

S A Evensen, P Stavem

    Acta Medica Scandinavica
    |January 1, 1978
    PubMed
    Summary

    Smouldering acute myelogenous leukemia (AML) is a distinct subtype characterized by fewer than 30% blasts and slow progression. This variant shows a median survival of 29 months, suggesting observation over immediate therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Skin biopsies for early diagnosis and prognosis of graft-versus-host disease in recipients of allogeneic stem cells from blood or bone marrow.

    Bone marrow transplantation·2004
    Same author

    Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study.

    Bone marrow transplantation·2003
    Same author

    Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints.

    Bone marrow transplantation·2002
    Same author

    Adoption of new health care services in Norway (1993-1997): specialists' self-assessment according to national criteria for priority setting.

    Health policy (Amsterdam, Netherlands)·2001
    Same author

    [Pain relief and euthanasia].

    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2000
    Same author

    A randomised study of allogeneic transplantation with stem cells from blood or bone marrow.

    Bone marrow transplantation·2000

    Area of Science:

    • Hematology
    • Oncology
    • Internal Medicine

    Background:

    • Acute myelogenous leukemia (AML) encompasses diverse clinical presentations.
    • Identifying distinct AML subtypes is crucial for tailored patient management.

    Observation:

    • A subset of 11 out of 195 AML patients met criteria for smouldering AML.
    • Smouldering AML patients had <30% bone marrow blasts and promyelocytes at diagnosis.
    • These patients exhibited slower disease progression, fewer initial infections, and less bleeding compared to typical AML.

    Findings:

    • Smouldering AML patients were older and presented with a less aggressive initial clinical picture.
    • The median survival time for smouldering AML patients was 29 months from diagnosis.
    • Disease progression to fulminant AML occurred later in the disease course.

    Implications:

    • Smouldering AML warrants careful observation rather than immediate aggressive antileukemic therapy.
    • Supportive care, including transfusions, antibiotics, and corticosteroids, should be administered as needed.
    • Distinguishing smouldering AML may refine treatment strategies and improve patient outcomes.

    Related Experiment Videos